Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Strengthens Intellectual Property Estate for REQORSA Oncology Program with Immune Checkpoint Inhibitors AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASD...
How does Genprex's IP position compare to other gene‑therapy companies, and could it enable licensing or partnership opportunities?
What is the expected timeline for clinical milestones and potential revenue from the REQORSA oncology program with PD‑1/PD‑L1 antibodies?
How will the expanded patent portfolio for Reqorsa® affect Genprex's valuation and near‑term stock price?
6 days ago